PTC Therapeutics HD

PTC Therapeutics is a global commercial-stage biopharmaceutical company dedicated to the discovery and development of clinically differentiated medicines for rare disorders. The company utilizes several proprietary technology platforms, including its RNA-directed nucleoside analog and splicing modifier technologies, to target a variety of genetic diseases. PTC's commercial portfolio includes treatments for Duchenne muscular dystrophy (DMD) and Aromatic L-amino acid decarboxylase (AADC) deficiency, while its robust pipeline features PTC518, a promising small molecule for Huntington's disease. By focusing on high-unmet-need rare diseases, PTC Therapeutics aims to provide life-changing therapies to patients worldwide.